CD8A and breast carcinoma: Oridonin+PD-1 treatment resulted in more CD8+ T TILs and increased numbers of IFN-γ+CD8+ T cells and granzyme B+CD8+ T cells, showing that oridonin improves the antitumor activity of anti-PD-1 in breast cancer.